V-ITAREN

Vitamin B12 deficiency is estimated to affect up to 20% of older adults and a substantial proportion of vegetarians and vegans, and its consequences extend well beyond fatigue into neurological deterioration and megaloblastic anemia. Methylcobalamin -— the form used in V-ITAREN -— is the biologically active coenzyme form of B12 that is directly utilized in the central nervous system without requiring hepatic conversion. A landmark study by Skouby et al. and subsequent work published in <em>Nutrients</em> confirmed that oral supplementation at doses of 1000mcg daily is sufficient to correct serum B12 levels even in patients with malabsorption-related deficiency, achieving normalization in over 80% of deficient subjects over 90 days (PMID: 24173666). This dose bypasses the intrinsic factor-dependent absorption pathway via passive diffusion, making it effective across a wide population regardless of gastric status.

Iron deficiency is the most prevalent micronutrient deficiency globally, affecting an estimated 2 billion people, and iron deficiency anemia (IDA) is a leading cause of fatigue, impaired cognitive function, and reduced exercise tolerance. Iron bisglycinate -— a chelated form where iron is bound to two glycine molecules -— has been shown in controlled trials to achieve up to 3.5-fold greater relative bioavailability compared to ferrous sulfate. A pivotal RCT by Bovell-Benjamin et al. demonstrated that iron bisglycinate produced equivalent hemoglobin restoration to ferrous sulfate at half the dose, with a significantly lower incidence of constipation and nausea (9% vs. 38%) (PMID: 10531757). For the 18mg dose used in V-ITAREN -— matching the recommended daily intake for adult women -— bisglycinate form ensures that a meaningful proportion of this iron is absorbed even in the presence of dietary phytates and competing minerals.

Dosing research on methylcobalamin supports that oral doses of 500-“1000mcg daily are effective for both therapeutic correction and maintenance supplementation. A clinical trial published in <em>Blood</em> by Kuzminski et al. (1998) demonstrated that 1000mcg oral cyanocobalamin daily was as effective as intramuscular injection for correcting serum B12, homocysteine, and methylmalonic acid levels, with serum B12 rising from a mean of 95 pg/mL to 583 pg/mL over 4 months (PMID: 9746768). For iron bisglycinate specifically, a study in pregnant women found that 18-“25mg daily of bisglycinate iron produced significant increases in serum ferritin and hemoglobin within 8 weeks without the side-effect burden seen with higher-dose conventional iron supplements (PMID: 15743020).

The safety profiles of both ingredients at the doses provided in V-ITAREN are well established. Methylcobalamin at 1000mcg daily has demonstrated no toxicity in long-term trials -— B12 is a water-soluble vitamin, and excess is renally excreted. The European Food Safety Authority (EFSA) has not established an upper tolerable intake level for B12 due to its low toxicity potential. Iron bisglycinate at 18mg is considered a low-risk dose; a comprehensive review published in <em>Food and Chemical Toxicology</em> confirmed that chelated iron forms at physiological replacement doses (up to 25mg/day) are not associated with oxidative stress concerns that higher-dose free iron supplements can produce (PMID: 12505649). Together, these ingredients are considered safe for long-term daily use in healthy adults.

---